Schaumburg, Ill.-based APP Pharmaceuticals on Friday announced that the FDA has cleared its Caffeine Citrate Oral Solution at 20 mg/ml for the short-term treatment of apnea in premature infants and its injectable bleomycin sulfate for use in combination with other cancer medications. The drugs are generic equivalents of Bedford Laboratories' Cafcit Oral Solution and Bristol-Myers Squibb Co.'s Blenoxane, respectively.

Related Summaries